Pharmacoeconomics applied to chronic hepatitis C
AUTOR(ES)
Tatsch, Fernando Franciosi, Sette Jr., Hoel, Vianna, Denizar
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2006-02
RESUMO
Life expectancy has increased over the last century as it had never been before. This is the result of a combination of many favorable variables such as level of education, improved socio-economic environment and development of medicine. However, new improvements demand heavy investment. Thus, the incorporation of medical technology became a health and economic issue. The pharmacoeconomic knowledge field is being developed to help in the analysis of medical costs and patient needs. The applies to hepatitic C, a common and chronic worldwide disease. In this article, the authors describe the rational behind this type of health economic analysis and review a hepatitis C model. Overall, in a non-Brazilian scenario, it was demonstrated that peginterferon alfa-2a (40KD) is cost effective in the treatment of HCV disease.
